High - Dose Chemotherapy Plus Transplant Not Recommended for DLBCL: The results of an Italian study report that treatment of high - risk diffuse large B - cell lymphoma (DLBCL) with abbreviated course of rituximab dose - dense chemotherapy plus high -
dose cytarabine, mitoxantrone, and dexamethasone (R - MAD) plus carmustine, etoposide, cytarabine, and melphalan (BEAM) plus autologous stem cell transplantation compared with a full course of rituximab dose - dense chemotherapy did not improve overall survival.
AAML 0531 included the same four courses plus a fifth course containing high -
dose cytarabine.
A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine (AZA) or low -
dose cytarabine (LDAC) is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.
A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine or low -
dose cytarabine is active in patients with FLT3 - ITD mutated myeloid leukemias, according to a new study.
Not exact matches
The 28 - day treatment cycle included AZA 75 mg / m2 subcutaneously or intravenously for 7 days per cycle, or
cytarabine 20 mg subcutaneously twice daily for 10 days per cycle along with quizartinib at two planned
dose levels: 60 mg (
dose level 1) or 90 mg orally daily (
dose level 2), uninterrupted.
This means steroids in high
doses and other drugs such as azathioprine,
cytarabine, mycophenolate, cyclosporin, and cyclophosphamide.